Coverage at a glance
| Indication | Coverage |
|---|---|
| Obesity / weight management | Covered with prior authorization |
Blue Shield of California lists Wegovy on its weight management agents pharmacy policy, so where a plan includes the weight-loss drug benefit, Wegovy is covered for chronic weight management after prior authorization. The policy sets a body mass index of 30 or higher, or 27 or higher with a weight-related condition such as hypertension, type 2 diabetes, dyslipidemia, or sleep apnea treated with CPAP, and it requires at least 6 months of a reduced-calorie diet, activity, and behavior-change program within the past year. Whether the drug is covered at all depends on the member's benefit: many commercial and self-funded employer plans exclude weight-loss drugs, and Blue Shield's own policy states that the member's specific benefit may affect drug coverage. Reauthorization requires at least 5% weight loss from baseline.
Source: Weight Management Agents: Blue Shield of California pharmacy benefit drug policy (effective 09/27/2023, last revised 11/29/2023). Verified August 28, 2026.
Plan type: Commercial non-Medicare.
What it costs once they say yes. With commercial insurance the manufacturer savings card takes Wegovy to as little as $25 a month. Your plan sets the copay before the card applies. What Wegovy costs with your plan.
This varies by plan. Blue Shield's weight management agents policy sets the clinical rules, but coverage turns on whether the employer group bought the weight-loss drug benefit. The policy itself states that the member's specific benefit may affect drug coverage, and many commercial and self-funded plans exclude anti-obesity drugs. Members should confirm with their plan that weight-loss medication is a covered benefit before assuming the clinical criteria apply.
Coverage by indication
| BMI threshold | 30, or 27 with a weight-related comorbidity |
What the prior authorization needs:
- Body mass index of 30 or higher, or 27 or higher with a weight-related condition such as hypertension, type 2 diabetes, coronary artery disease, dyslipidemia, stroke, osteoarthritis, metabolic syndrome, prediabetes, PCOS, NASH, or sleep apnea treated with CPAP
- Used as an adjunct to a reduced-calorie diet and increased physical activity
- Documented participation in a comprehensive lifestyle program (reduced-calorie diet, increased physical activity, and behavioral modification) for at least 6 months within the past year
- Evaluated by a physician to rule out other endocrine causes of obesity, and meets the FDA-approved age for use
- Not used in combination with another weight-loss agent or another GLP-1 receptor agonist
- No bariatric surgery within the previous 12 months
- Prior authorization required; initial approval covers 7 months, and reauthorization requires at least 5% weight loss from baseline
- Coverage applies only if the member's plan includes the weight-loss drug benefit
Source: Weight Management Agents: Blue Shield of California pharmacy benefit drug policy (effective 09/27/2023, last revised 11/29/2023). payer_medication_policy. Verified August 28, 2026.
Ozempic, Mounjaro and Rybelsus on Blue Shield of California plans
Ozempic, Mounjaro and Rybelsus are approved for type 2 diabetes, not weight loss.
Does Blue Shield of California cover Ozempic?
Yes, with prior approval. Blue Shield of California pays for Ozempic once your prescriber gets the plan to sign off.
Blue Shield of California covers Ozempic (semaglutide) for type 2 diabetes with prior authorization. On the commercial drug formulary it sits at Tier 2 with prior authorization and quantity limits, and the medical necessity policy also requires step therapy: a confirmed type 2 diabetes diagnosis (A1C of 6.5% or higher) plus a documented trial of metformin, unless the member needs combination therapy or has high-risk cardiovascular disease. Ozempic is not covered for weight loss, because it is FDA-approved for type 2 diabetes only. Wegovy is the higher-dose semaglutide indicated for weight loss.
Verified August 27, 2026.
What Blue Shield of California requires for Ozempic
| Step therapy |
What the prior authorization needs:
- Confirmed type 2 diabetes diagnosis (A1C of 6.5% or higher, fasting blood glucose of 126 mg/dL or higher, or oral glucose tolerance test of 200 mg/dL or higher)
- Documented inadequate response, intolerable side effect, or contraindication to metformin, OR need for combination therapy with an A1C of 7.5% or higher, OR atherosclerotic cardiovascular disease at high risk
- Not used in combination with another GLP-1 receptor agonist
- Dose does not exceed the FDA-label maximum
- Prior authorization required; approval lasts one year
- Tier 2 on the commercial formulary with quantity limits (for example, 2 pens per 28 days)
Source: Glucagon-Like Peptide-1 (GLP-1) Agents, Commercial: BSC Medication Policy to Determine Medical Necessity (effective 5/3/2023). policy. Verified August 27, 2026.
Does Blue Shield of California cover Mounjaro?
Yes, with prior approval. Blue Shield of California pays for Mounjaro once your prescriber gets the plan to sign off.
Blue Shield of California covers Mounjaro (tirzepatide) for type 2 diabetes under its commercial pharmacy benefit, but only after prior authorization and step therapy. A member needs a confirmed type 2 diabetes diagnosis (for example, an A1C of 6.5% or higher), a documented problem with metformin or a need for combination therapy at an A1C of 7.5% or higher, and inadequate response or intolerance to two preferred GLP-1 agents such as Ozempic, Trulicity, Victoza, or Rybelsus. Mounjaro is FDA-approved for type 2 diabetes only, so Blue Shield does not cover it for weight loss. Zepbound is the tirzepatide product approved for weight loss, and it is reviewed under a separate policy.
Verified August 27, 2026.
What Blue Shield of California requires for Mounjaro
| Step therapy |
What the prior authorization needs:
- Type 2 diabetes confirmed by an A1C of 6.5% or higher, a fasting blood glucose of 126 mg/dL or higher, or an oral glucose tolerance test of 200 mg/dL or higher.
- Not used in combination with another GLP-1 receptor agonist.
- Inadequate response, intolerable side effect, or contraindication with metformin, or the patient requires combination therapy and has an A1C of 7.5% or higher.
- Inadequate response or intolerable side effect with two preferred GLP-1 agents (Ozempic, Trulicity, Victoza, or Rybelsus).
- Dose does not exceed 15 mg per 0.5 mL subcutaneously weekly.
- Approval lasts one year.
Source: Mounjaro - Commercial: BSC Medication Policy to Determine Medical Necessity. payer_medication_policy. Verified August 27, 2026.
Does Blue Shield of California cover Rybelsus?
Yes, with prior approval. Blue Shield of California pays for Rybelsus once your prescriber gets the plan to sign off.
Blue Shield of California covers Rybelsus (oral semaglutide) for type 2 diabetes with prior authorization. The commercial GLP-1 medical necessity policy lists Rybelsus as a preferred GLP-1 agent and requires a confirmed type 2 diabetes diagnosis (an A1C of 6.5% or higher) plus step therapy: an inadequate response, intolerable side effect, or contraindication to metformin, unless the member needs combination therapy at an A1C of 7.5% or higher. Rybelsus is not covered for weight loss, because it is FDA-approved for type 2 diabetes only. Wegovy is the semaglutide product indicated for weight loss.
Verified August 28, 2026.
What Blue Shield of California requires for Rybelsus
| Step therapy |
What the prior authorization needs:
- Rybelsus is a preferred GLP-1 agent on the commercial medical necessity policy
- Type 2 diabetes confirmed by an A1C of 6.5% or higher, a fasting blood glucose of 126 mg/dL or higher, or an oral glucose tolerance test of 200 mg/dL or higher
- Documented inadequate response, intolerable side effect, or contraindication to metformin, OR a need for combination therapy with an A1C of 7.5% or higher
- Not used in combination with another GLP-1 receptor agonist
- Dose does not exceed the FDA-label maximum
- Prior authorization required; approval lasts one year
Source: Glucagon-Like Peptide-1 (GLP-1) Agents, Commercial: BSC Medication Policy to Determine Medical Necessity (effective 5/3/2023). policy. Verified August 28, 2026.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it. Plans that approve reassess at renewal, so know your long-term maintenance dose before you start.
- Browse the prior-authorization letter library for a template that matches your plan and indication.
- Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
- If the prior-authorization request is denied, the appeal letter library has templates by denial reason, covering peer-to-peer review, Level 1 and Level 2 internal appeal, and external review.
- Call the number on your insurance card and ask whether your specific plan includes the weight-management drug benefit before you submit.
- If your plan does not cover the indication you need, compare cash prices in the cost guide or check whether a clinical trial near you fits. Neither one goes through your insurer. Clinical trials cost nothing and many pay you for your time.
What it costs without insurance
The programs below bill you directly. Prices checked every Monday.
Frequently asked questions
Does Blue Shield of California cover Wegovy?
Blue Shield of California lists Wegovy on its weight management agents pharmacy policy, so where a plan includes the weight-loss drug benefit, Wegovy is covered for chronic weight management after prior authorization. The policy sets a body mass index of 30 or higher, or 27 or higher with a weight-related condition such as hypertension, type 2 diabetes, dyslipidemia, or sleep apnea treated with CPAP, and it requires at least 6 months of a reduced-calorie diet, activity, and behavior-change program within the past year. Whether the drug is covered at all depends on the member's benefit: many commercial and self-funded employer plans exclude weight-loss drugs, and Blue Shield's own policy states that the member's specific benefit may affect drug coverage. Reauthorization requires at least 5% weight loss from baseline. This reflects the published policy verified August 2026.
What does Blue Shield of California require to approve Wegovy?
For obesity / weight management: The BMI requirement is 30, or 27 with a weight-related comorbidity.
Why might Blue Shield of California deny Wegovy even if I meet the criteria?
Blue Shield's weight management agents policy sets the clinical rules, but coverage turns on whether the employer group bought the weight-loss drug benefit. The policy itself states that the member's specific benefit may affect drug coverage, and many commercial and self-funded plans exclude anti-obesity drugs. Members should confirm with their plan that weight-loss medication is a covered benefit before assuming the clinical criteria apply.
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources; those rows are marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit. Those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
